LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

Conditions

Li Fraumeni Syndrome

Keywords

patients with Li Fraumeni syndrome

Brief summary

The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.

Marine Fidelle, Déborah Suissa, Aline Renneville, Tarek Ben-Ahmed, Sylvère Durand et al. (15 authors)

Cancer Research2025-04-21

10.1158/1538-7445.am2025-6423

171MO Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development

T. Ben Ahmed, Marine Fidelle, I. Lahmar, A-L. Mallard de la Varende, Eleni Karamouza et al. (9 authors)

ESMO Open2023-05-01

10.1016/j.esmoop.2023.101448

Evaluation of whole body MRI for early detection of cancer in TP53 mutation carriers: Final results of the LIFSCREEN study.

Olivier Caron, Eleni Karamouza, Stéphanie Foulon, Patrick R. Benusiglio, Valérie Bonadona et al. (20 authors)

Journal of Clinical Oncology2018-05-201 citations

10.1200/jco.2018.36.15_suppl.1527

The 2016 Li-Fraumeni syndrome cancer spectrum.

Olivier Caron, Thierry Frébourg, Patrick R. Benusiglio, Laurence Faivre, Catherine Dugast et al. (18 authors)

Journal of Clinical Oncology2016-05-203 citations

10.1200/jco.2016.34.15_suppl.1535

Interventions

OTHERwhole body MRI

whole body MRI at inclusion, one and two years

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

5 Years to 71 Years

Healthy volunteers

No

Inclusion criteria

* P53 mutation

Design outcomes

Primary

Measure	Time frame	Description
cancer incidence	3 years	cancer incidence during the first 3 years

Countries

France

Outcome results

None listed